Louis E Murdock, MD | |
600 N Robbins Rd, Ste 100, Boise, ID 83702 | |
(208) 383-0201 | |
(208) 489-4300 |
Full Name | Louis E Murdock |
---|---|
Gender | Male |
Speciality | Orthopaedic Surgery - Hand Surgery |
Location | 600 N Robbins Rd, Boise, Idaho |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1184635088 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207XS0106X | Orthopaedic Surgery - Hand Surgery | M-8161 (Idaho) | Primary |
Entity Name | St Lukes Clinic-treasure Valley Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1326336058 PECOS PAC ID: 4981878402 Enrollment ID: O20111119000045 |
News Archive
Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.
Based on a study of 85 Gulf War veterans, Veterans Affairs researchers in Minneapolis have developed a tentative panel of blood markers they say can verify a diagnosis of Gulf War Illness with 90 percent accuracy.
CrystalGenomics, Inc., a novel drug R&D company announced today that the Phase I SAD (Single Ascending Dose) study for its novel antibiotic candidate, CG400549, has been successfully completed in Europe.
Four Forsyth scientists have received grants from the latest round of National Institutes of Health stimulus funding through the American Recovery and Reinvestment Act (ARRA) of 2009. To date, Forsyth has received 13 ARRA grants totally nearly $6.4 million. The recent round of funding includes three highly competitive 'Challenge Grants'. The NIH received 22,000 submissions in the Challenge Grant competition ― only about 500 were funded.
One approach to developing tumor-specific drug delivery agents is to create nanomaterials that release a therapeutic payload only after reaching their intended target.
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Louis E Murdock, MD 190 E Bannock St, Boise, ID 83712-6241 Ph: (208) 383-0201 | Louis E Murdock, MD 600 N Robbins Rd, Ste 100, Boise, ID 83702 Ph: (208) 383-0201 |
News Archive
Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.
Based on a study of 85 Gulf War veterans, Veterans Affairs researchers in Minneapolis have developed a tentative panel of blood markers they say can verify a diagnosis of Gulf War Illness with 90 percent accuracy.
CrystalGenomics, Inc., a novel drug R&D company announced today that the Phase I SAD (Single Ascending Dose) study for its novel antibiotic candidate, CG400549, has been successfully completed in Europe.
Four Forsyth scientists have received grants from the latest round of National Institutes of Health stimulus funding through the American Recovery and Reinvestment Act (ARRA) of 2009. To date, Forsyth has received 13 ARRA grants totally nearly $6.4 million. The recent round of funding includes three highly competitive 'Challenge Grants'. The NIH received 22,000 submissions in the Challenge Grant competition ― only about 500 were funded.
One approach to developing tumor-specific drug delivery agents is to create nanomaterials that release a therapeutic payload only after reaching their intended target.
› Verified 3 days ago
Tracye Jean-marie Lawyer, MD, PHD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8950 W Emerald St Ste 168, Boise, ID 83704 Phone: 208-321-1209 Fax: 208-321-1211 | |
Dustin I Judd, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 600 N Robbins Rd, Suite 100, Boise, ID 83702 Phone: 208-383-0201 | |
Dr. Michael Glover, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 500 W Fort St, Mail Code #112, Boise, ID 83702 Phone: 208-422-1000 Fax: 208-422-1082 | |
Jeffrey D Smith, PA C Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 7979 W Rifleman St, Boise, ID 83704 Phone: 208-989-0598 | |
Howard A King, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 600 N Robbins Rd, Ste 100, Boise, ID 83702 Phone: 208-383-0201 Fax: 208-489-4300 | |
Dr. Jeffrey Glenn Hessing, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 8854 W Emerald St, Suite 140, Boise, ID 83704 Phone: 208-327-4790 Fax: 208-367-4888 | |
Dr. Kirk J Lewis, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1188 University Dr, Boise, ID 83706 Phone: 208-336-8250 Fax: 208-345-9514 |